Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients.
Department of Ophthalmology, Osaka University Medical School, Japan.
BACKGROUND--Marked variations in cell size (polymegethism) and shape (pleomorphism) are characteristic of the corneal endothelium in diabetic patients and animals. METHOD--Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112. RESULTS--Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment. In contrast, no change in endothelial morphology was noted in five eyes from five patients who received placebo. CONCLUSION--These observations suggest that aldose reductase may be involved in the aetiology of corneal endothelial variations in diabetic patients.
Relevant Article
- Topical aldose reductase inhibitor.
- D Coster
Br. J. Ophthalmol. 1995 79: 1064-1065.[PDF]
This article has been cited by other articles:
-
Kaji, Y
(2005). Prevention of diabetic keratopathy. Br. J. Ophthalmol.
89: 254-255
[Full Text] -
Kaji, Y., Usui, T., Oshika, T., Matsubara, M., Yamashita, H., Araie, M., Murata, T., Ishibashi, T., Nagai, R., Horiuchi, S., Amano, S.
(2000). Advanced Glycation End Products in Diabetic Corneas. IOVS
41: 362-368
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
